nach oben

Erschienen in:

01.05.2013 | Original Article

Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life

verfasst von: Pelin Oktayoglu, Serda Em, Mehmet Tahtasiz, Mehtap Bozkurt, Demet Ucar, Levent Yazmalar, Kemal Nas, İbrahim Yardımeden, Figen Cevik, Yusuf Celik, Nuriye Mete

Erschienen in: Rheumatology International | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

This study was carried out to determine the serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis (AS) and to evaluate its correlation with disease activity and quality of life. According to our knowledge, it is the first trial evaluating HMGB1 levels in AS. Serum samples of 30 patients (18 males and 12 females) with AS and 29 healthy controls (HC) (15 females and 14 males) were collected. HMGB1 levels were measured by enzyme-linked immunosorbent assay, activity of disease was assessed according to the Bath AS Disease Activity Index (BASDAI), and functional status of patients was evaluated with Bath AS Functional Index (BASFI). Modified Schober, chest expansion values and AS Quality of Life Questionnaire (ASQoL) scores were noted. The serum levels of HMGB1 were obtained significantly increased in AS patients compared to HC (p < 0.05). There was no significant correlation between HMGB1 levels and ESR (p > 0.05), and CRP (p > 0.05) values. BASDAI, BASFI and ASQoL scores were also not correlated with serum levels of HMGB1 (p > 0.05). Our results suggest that HMGB1 might play an important role in the pathogenesis of AS; however, it seems not to be a good candidate for reflecting disease activity, functional abilities and the quality of life in patients with AS; on the other hand, the increased levels of HMGB1 in patients may open a new dimension for targeting this cytokine as a new therapy option in AS.

Gardner DL (1992) Reactive and postinfective arthritis and seronegative spondyloarthropathy. In: Gardner DL (ed) Pathological basis of the connective tissue diseases. London, pp 763–795

Pöllänen R, Sillat T, Pajarinen J et al (2009) Microbial antigens mediate HLA-B27 diseases via TLRs. J Autoimmun 32:172–177PubMedCrossRef

Cruickshank B (1956) Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 71:73–84PubMedCrossRef

Ball J (1971) Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 30:213–223PubMedCrossRef

Sieper J, Appel H, Braun J et al (2008) Critical appraisal of assessment of structural damage in ankylosing spondylitis. Arthritis Rheum 58:649–656PubMedCrossRef

Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5PubMedCrossRef

Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209PubMedCrossRef

Taniguchi N, Kawahara K, Yone K et al (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971–981PubMedCrossRef

Chun yun ma C, MaJiao Y, Zhang J et al (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 32:395–402CrossRef

10.

Yu M, Wang H, Ding A et al (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174–179PubMedCrossRef

11.

Park JS, Gamboni-Robertson F, He Q et al (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290:917–924CrossRef

12.

Anderson U, Wang H, Palmblad K et al (2000) High mobility group 1 protein (HMG 1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565–570CrossRef

13.

Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1, sIL-2R, IL-6 and TNF- alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215PubMedCrossRef

14.

Gratacos J, Collado A, Fiella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheum 33:927–931CrossRef

15.

Taniguchi N, Yoshida K, Ito T et al (2007) The stage specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol 27:5650–5663PubMedCrossRef

16.

Yang J, Shah R, Robling AG, Templeton E et al (2008) HMGB1 is a bone-active cytokine. J Cell Physiol 214:730–739PubMedCrossRef

17.

Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291PubMed

18.

Akkoc Y, Karatepe AG, Akar S et al (2005) A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 25:280–284PubMedCrossRef

19.

Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed

20.

Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef

21.

Duruoz T, Doward L, Cerrahoglu L et al (2008) Translation and validation of the Turkish version of the ankylosing spondylitis quality of life (ASQoL) Questionnaire. Abstract Book, EULARl

22.

Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342PubMedCrossRef

23.

Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505PubMedCrossRef

24.

Braun J, van den Berg R, Baraliakos X et al (2010) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896–904CrossRef

25.

Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRef

26.

Yang H, Wang H, Tracey KJ (2001) HMG-1 rediscovered as a cytokine. Shock 15:247–253PubMedCrossRef

27.

Andersson U, Erlandsson-Harris H (2004) HMGB1 is a potent trigger of arthritis. J Intern Med 255:344–350PubMedCrossRef

28.

Assassi S, Reveille JD, Arnett FC et al (2011) Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5. J Rheumatol 38:87–98PubMedCrossRef

29.

Ek M, Popovic K, Harris HE et al (2006) Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 54:2289–2294PubMedCrossRef

30.

Ahn JK, Cha HS, Bae EK et al (2011) Extracellular high-mobility group box 1 is increased in patients with Behçet’s disease with intestinal involvement. J Korean Med Sci 26:697–700PubMedCrossRef

31.

Liu B, Guo CY, Liu WQ et al (2005) The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis. Zhonghua Nei Ke Za Zhi 44:566–569PubMed

32.

Yildirim K, Erdal A, Karatay S et al (2004) Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 97:350–353PubMedCrossRef

33.

Spoorenberg A, van der Heijde D, de Klerk E et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984PubMed

Titel: Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life
verfasst von: Pelin Oktayoglu
Serda Em
Mehmet Tahtasiz
Mehtap Bozkurt
Demet Ucar
Levent Yazmalar
Kemal Nas
İbrahim Yardımeden
Figen Cevik
Yusuf Celik
Nuriye Mete
Publikationsdatum: 01.05.2013
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 5/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-012-2578-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Sexuality of men with fibromyalgia: what are the factors that cause sexual dysfunction?

Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population

The co-occurrence of Hashimoto thyroiditis in primary Sjogren’s syndrome defines a subset of patients with milder clinical phenotype

High frequency of inflammatory back pain and other features of spondyloarthritis in patients with rheumatoid arthritis

Targeting interleukin-33 in rheumatoid arthritis